Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06890598
Registration number
NCT06890598
Ethics application status
Date submitted
18/03/2025
Date registered
24/03/2025
Date last updated
4/11/2026
Titles & IDs
Public title
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Query!
Scientific title
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Query!
Additional trial identifiers [1]
0
0
2024-512302-25-00
Query!
Additional trial identifiers [2]
0
0
18763
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SUNRAY-02
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Carcinoma, Non-Small-Cell Lung
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - Olomorasib
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Durvalumab
Treatment: Drugs - Placebo
Experimental: Part A: Olomorasib + Pembrolizumab - Participants will receive olomorasib administered orally in combination with pembrolizumab intravenously (IV) for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.
Placebo comparator: Part A: Placebo + Pembrolizumab - Participants will receive placebo administered orally in combination with pembrolizumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.
Experimental: Part B: Olomorasib + Durvalumab - Participants will receive olomorasib administered orally in combination with durvalumab administered IV for up to 1 year followed by olomorasib alone for up to 3 years of total treatment.
Placebo comparator: Part B: Placebo + Durvalumab - Participants will receive placebo administered orally in combination with durvalumab administered IV for up to 1 year followed by placebo alone for up to 3 years of total treatment.
Treatment: Drugs: Olomorasib
Administered orally.
Treatment: Drugs: Pembrolizumab
Administered intravenously (IV).
Treatment: Drugs: Durvalumab
Administered IV.
Treatment: Drugs: Placebo
Administered orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Part A: Disease-Free Survival (DFS) by Investigator Assessment
Query!
Assessment method [1]
0
0
DFS by Investigator Assessment
Query!
Timepoint [1]
0
0
Randomization to disease recurrence or death from any cause (Estimated as approximately 4 years).
Query!
Primary outcome [2]
0
0
Part B: Progression-Free Survival (PFS) by BICR
Query!
Assessment method [2]
0
0
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)
Query!
Timepoint [2]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Query!
Secondary outcome [1]
0
0
Part A & B: Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS
Query!
Timepoint [1]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 5 years).
Query!
Secondary outcome [2]
0
0
Part A & B: Change from baseline in health-related quality of life (HRQoL), measured by European Organization for Research & Treatment of CancerQualityofLifeQuestionnaire-Core 30 (EORTC QLQ-C30)
Query!
Assessment method [2]
0
0
Change from baseline in HRQoL, measured by the EORTC QLQ-C30
Query!
Timepoint [2]
0
0
Randomization through end of treatment (Estimated as approximately 3 years).
Query!
Secondary outcome [3]
0
0
Part B: PFS by Investigator
Query!
Assessment method [3]
0
0
PFS per RECIST v1.1 by Investigator
Query!
Timepoint [3]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years)
Query!
Secondary outcome [4]
0
0
Part B: Objective Response Rate (ORR) per RECIST 1.1 by BICR and Investigator
Query!
Assessment method [4]
0
0
ORR per RECIST 1.1 by BICR and Investigator
Query!
Timepoint [4]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Query!
Secondary outcome [5]
0
0
Part B: Duration of Response (DOR) per RECIST 1.1 by BICR and Investigator
Query!
Assessment method [5]
0
0
DOR per RECIST 1.1 by BICR and Investigator
Query!
Timepoint [5]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Query!
Secondary outcome [6]
0
0
Part B: Disease Control Rate (DCR) per RECIST 1.1 by BICR and Investigator
Query!
Assessment method [6]
0
0
DCR per RECIST 1.1 by BICR and Investigator
Query!
Timepoint [6]
0
0
Randomization to disease progression or death from any cause (Estimated as approximately 3 years).
Query!
Secondary outcome [7]
0
0
Part B: Time to Response (TTR) per RECIST 1.1 by BICR and Investigator
Query!
Assessment method [7]
0
0
TTR per RECIST 1.1 by BICR and Investigator
Query!
Timepoint [7]
0
0
Randomization until the date that measurement criteria for CR or PR (whichever is first recorded) are first met (Estimated as approximately 3 years).
Query!
Secondary outcome [8]
0
0
Part B: Progression-Free Survival 2 (PFS2) by investigator assessment
Query!
Assessment method [8]
0
0
PFS2 by investigator assessment
Query!
Timepoint [8]
0
0
Randomization to disease progression on next line of treatment or death from any cause (Estimated as approximately 3 years).]
Query!
Secondary outcome [9]
0
0
Part B: Changes in Non-Small Cell Lung Cancer (NSCLC)-related symptoms, measured by the NSCLC-Symptom Assessment Questionnaire (SAQ)
Query!
Assessment method [9]
0
0
Changes in NSCLC-related symptoms, measured by the NSCLC-SAQ
Query!
Timepoint [9]
0
0
Randomization through end of treatment (Estimated as approximately 3 years).
Query!
Secondary outcome [10]
0
0
Part B: Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ
Query!
Assessment method [10]
0
0
Time to worsening of NSCLC-related symptoms, as measured by NSCLC-SAQ
Query!
Timepoint [10]
0
0
Randomization through end of treatment (Estimated as approximately 3 years).
Query!
Secondary outcome [11]
0
0
Part B: Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ
Query!
Assessment method [11]
0
0
Changes in patient-reported pulmonary symptoms of cough, chest pain, and dyspnea, measured by NSCLC-SAQ
Query!
Timepoint [11]
0
0
Randomization through end of treatment (Estimated as approximately 3 years).
Query!
Eligibility
Key inclusion criteria
* Histological or cytological confirmation of NSCLC.
* Part A
1. Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.
2. Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection.
* Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
* Must have disease with evidence of KRAS G12C mutation.
* Must have known programmed death-ligand 1 (PD-L1) expression
* Must have an ECOG performance status of 0 or 1.
* Able to swallow oral medication.
* Must have adequate laboratory parameters.
* Contraceptive use should be consistent with local regulations for those participating in clinical studies.
* Women of childbearing potential must
* Have a negative pregnancy test.
* Not be breastfeeding during treatment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Have known, actionable changes in the EGFR or ALK genes.
* Have another type of cancer that is progressing or required active treatment within the past 2 years before screening.
* Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed.
* Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/03/2025
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/02/2032
Query!
Actual
Query!
Sample size
Target
700
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Icon Cancer Centre Wesley - Auchenflower
Query!
Recruitment hospital [2]
0
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment hospital [3]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [4]
0
0
ICON Cancer Centre - Kurralta Park - Kurralta Park
Query!
Recruitment hospital [5]
0
0
Tamworth Hospital - North Tamworth
Query!
Recruitment hospital [6]
0
0
Sir Charles Gairdner Hospital - Perth
Query!
Recruitment hospital [7]
0
0
Goulburn Valley Health - Shepparton
Query!
Recruitment hospital [8]
0
0
Latrobe Regional Health - Traralgon
Query!
Recruitment postcode(s) [1]
0
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [2]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [4]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [5]
0
0
2340 - North Tamworth
Query!
Recruitment postcode(s) [6]
0
0
6009 - Perth
Query!
Recruitment postcode(s) [7]
0
0
3630 - Shepparton
Query!
Recruitment postcode(s) [8]
0
0
3844 - Traralgon
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
District of Columbia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Maryland
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Massachusetts
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Michigan
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Hampshire
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Jersey
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Ohio
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
South Carolina
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Dakota
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Vermont
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Wisconsin
Query!
Country [33]
0
0
Austria
Query!
State/province [33]
0
0
Graz
Query!
Country [34]
0
0
Austria
Query!
State/province [34]
0
0
Linz
Query!
Country [35]
0
0
Austria
Query!
State/province [35]
0
0
Vienna
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Auderghem
Query!
Country [37]
0
0
Belgium
Query!
State/province [37]
0
0
Edegem
Query!
Country [38]
0
0
Belgium
Query!
State/province [38]
0
0
Leuven
Query!
Country [39]
0
0
Belgium
Query!
State/province [39]
0
0
Roeselare
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
Barretos
Query!
Country [41]
0
0
Brazil
Query!
State/province [41]
0
0
Belém
Query!
Country [42]
0
0
Brazil
Query!
State/province [42]
0
0
Belo Horizonte
Query!
Country [43]
0
0
Brazil
Query!
State/province [43]
0
0
Bento Gonçalves
Query!
Country [44]
0
0
Brazil
Query!
State/province [44]
0
0
Campinas
Query!
Country [45]
0
0
Brazil
Query!
State/province [45]
0
0
Fortaleza
Query!
Country [46]
0
0
Brazil
Query!
State/province [46]
0
0
Londrina
Query!
Country [47]
0
0
Brazil
Query!
State/province [47]
0
0
Natal
Query!
Country [48]
0
0
Brazil
Query!
State/province [48]
0
0
Porto Alegre
Query!
Country [49]
0
0
Brazil
Query!
State/province [49]
0
0
Rio de Janeiro
Query!
Country [50]
0
0
Brazil
Query!
State/province [50]
0
0
São Paulo
Query!
Country [51]
0
0
Chile
Query!
State/province [51]
0
0
Providencia
Query!
Country [52]
0
0
Chile
Query!
State/province [52]
0
0
Santiago
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Anyang
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Beijing
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Changchun
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Changsha
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Chengdu
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Chongqing
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Foshan
Query!
Country [60]
0
0
China
Query!
State/province [60]
0
0
Guangzhou
Query!
Country [61]
0
0
China
Query!
State/province [61]
0
0
Hangzhou
Query!
Country [62]
0
0
China
Query!
State/province [62]
0
0
Harbin
Query!
Country [63]
0
0
China
Query!
State/province [63]
0
0
Jinan
Query!
Country [64]
0
0
China
Query!
State/province [64]
0
0
Linhai
Query!
Country [65]
0
0
China
Query!
State/province [65]
0
0
Liuzhou
Query!
Country [66]
0
0
China
Query!
State/province [66]
0
0
Luoyang
Query!
Country [67]
0
0
China
Query!
State/province [67]
0
0
Nanning
Query!
Country [68]
0
0
China
Query!
State/province [68]
0
0
Shanghai
Query!
Country [69]
0
0
China
Query!
State/province [69]
0
0
Shantou
Query!
Country [70]
0
0
China
Query!
State/province [70]
0
0
Shenzhen
Query!
Country [71]
0
0
China
Query!
State/province [71]
0
0
Suzhou
Query!
Country [72]
0
0
China
Query!
State/province [72]
0
0
Tianjin
Query!
Country [73]
0
0
China
Query!
State/province [73]
0
0
Wuhan
Query!
Country [74]
0
0
China
Query!
State/province [74]
0
0
Xi'an
Query!
Country [75]
0
0
China
Query!
State/province [75]
0
0
Zhongshan
Query!
Country [76]
0
0
Czechia
Query!
State/province [76]
0
0
Ostrava
Query!
Country [77]
0
0
Czechia
Query!
State/province [77]
0
0
Prague
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Bobigny
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Bron
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
La Tronche
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Lyon Cedex08
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Marseille
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Nice
Query!
Country [84]
0
0
France
Query!
State/province [84]
0
0
Paris
Query!
Country [85]
0
0
France
Query!
State/province [85]
0
0
Pessac
Query!
Country [86]
0
0
France
Query!
State/province [86]
0
0
Poitiers
Query!
Country [87]
0
0
France
Query!
State/province [87]
0
0
Reims
Query!
Country [88]
0
0
France
Query!
State/province [88]
0
0
Rennes
Query!
Country [89]
0
0
France
Query!
State/province [89]
0
0
Toulouse
Query!
Country [90]
0
0
France
Query!
State/province [90]
0
0
Vantoux
Query!
Country [91]
0
0
France
Query!
State/province [91]
0
0
Villejuif
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Berlin
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Chemnitz
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Cologne
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Erfurt
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Gauting
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Georgsmarienhütte
Query!
Country [98]
0
0
Germany
Query!
State/province [98]
0
0
Großhansdorf
Query!
Country [99]
0
0
Germany
Query!
State/province [99]
0
0
Halle
Query!
Country [100]
0
0
Germany
Query!
State/province [100]
0
0
Hamburg
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Heidelberg
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
Hemer
Query!
Country [103]
0
0
Germany
Query!
State/province [103]
0
0
Herne
Query!
Country [104]
0
0
Germany
Query!
State/province [104]
0
0
Leipzig
Query!
Country [105]
0
0
Germany
Query!
State/province [105]
0
0
Nuremberg
Query!
Country [106]
0
0
Germany
Query!
State/province [106]
0
0
Stuttgart
Query!
Country [107]
0
0
Germany
Query!
State/province [107]
0
0
Tübingen
Query!
Country [108]
0
0
Greece
Query!
State/province [108]
0
0
Athens
Query!
Country [109]
0
0
Greece
Query!
State/province [109]
0
0
Heraklion
Query!
Country [110]
0
0
Greece
Query!
State/province [110]
0
0
Larissa
Query!
Country [111]
0
0
Greece
Query!
State/province [111]
0
0
Pátrai
Query!
Country [112]
0
0
Greece
Query!
State/province [112]
0
0
Thessaloniki
Query!
Country [113]
0
0
Hungary
Query!
State/province [113]
0
0
Budapest
Query!
Country [114]
0
0
Hungary
Query!
State/province [114]
0
0
Farkasgyepu
Query!
Country [115]
0
0
India
Query!
State/province [115]
0
0
Ahmedabad
Query!
Country [116]
0
0
India
Query!
State/province [116]
0
0
Chennai
Query!
Country [117]
0
0
India
Query!
State/province [117]
0
0
Chhatrapati Sambhajinagar
Query!
Country [118]
0
0
India
Query!
State/province [118]
0
0
Mumbai
Query!
Country [119]
0
0
India
Query!
State/province [119]
0
0
Namakkal
Query!
Country [120]
0
0
India
Query!
State/province [120]
0
0
Patna
Query!
Country [121]
0
0
India
Query!
State/province [121]
0
0
Pune
Query!
Country [122]
0
0
India
Query!
State/province [122]
0
0
Thalassery
Query!
Country [123]
0
0
India
Query!
State/province [123]
0
0
Thiruvananthapuram
Query!
Country [124]
0
0
India
Query!
State/province [124]
0
0
Udaipur
Query!
Country [125]
0
0
India
Query!
State/province [125]
0
0
Varanasi
Query!
Country [126]
0
0
Israel
Query!
State/province [126]
0
0
Haifa
Query!
Country [127]
0
0
Israel
Query!
State/province [127]
0
0
Jerusalem
Query!
Country [128]
0
0
Israel
Query!
State/province [128]
0
0
Kfar Saba
Query!
Country [129]
0
0
Israel
Query!
State/province [129]
0
0
Ramat Gan
Query!
Country [130]
0
0
Italy
Query!
State/province [130]
0
0
Bari
Query!
Country [131]
0
0
Italy
Query!
State/province [131]
0
0
Catania
Query!
Country [132]
0
0
Italy
Query!
State/province [132]
0
0
Genova
Query!
Country [133]
0
0
Italy
Query!
State/province [133]
0
0
Meldola
Query!
Country [134]
0
0
Italy
Query!
State/province [134]
0
0
Milan
Query!
Country [135]
0
0
Italy
Query!
State/province [135]
0
0
Monza
Query!
Country [136]
0
0
Italy
Query!
State/province [136]
0
0
Naples
Query!
Country [137]
0
0
Italy
Query!
State/province [137]
0
0
Orbassano
Query!
Country [138]
0
0
Italy
Query!
State/province [138]
0
0
Rome
Query!
Country [139]
0
0
Italy
Query!
State/province [139]
0
0
Verona
Query!
Country [140]
0
0
Japan
Query!
State/province [140]
0
0
Bunkyo City
Query!
Country [141]
0
0
Japan
Query!
State/province [141]
0
0
Fukuoka
Query!
Country [142]
0
0
Japan
Query!
State/province [142]
0
0
Hidaka
Query!
Country [143]
0
0
Japan
Query!
State/province [143]
0
0
Himeji
Query!
Country [144]
0
0
Japan
Query!
State/province [144]
0
0
Hirakata
Query!
Country [145]
0
0
Japan
Query!
State/province [145]
0
0
Kanazawa
Query!
Country [146]
0
0
Japan
Query!
State/province [146]
0
0
Kashiwa
Query!
Country [147]
0
0
Japan
Query!
State/province [147]
0
0
Kobe
Query!
Country [148]
0
0
Japan
Query!
State/province [148]
0
0
Koto City
Query!
Country [149]
0
0
Japan
Query!
State/province [149]
0
0
Kyoto
Query!
Country [150]
0
0
Japan
Query!
State/province [150]
0
0
Nagaizumi-cho,Sunto-gun
Query!
Country [151]
0
0
Japan
Query!
State/province [151]
0
0
Nagoya
Query!
Country [152]
0
0
Japan
Query!
State/province [152]
0
0
Natori
Query!
Country [153]
0
0
Japan
Query!
State/province [153]
0
0
Niigata
Query!
Country [154]
0
0
Japan
Query!
State/province [154]
0
0
Sakai
Query!
Country [155]
0
0
Japan
Query!
State/province [155]
0
0
Sapporo
Query!
Country [156]
0
0
Japan
Query!
State/province [156]
0
0
Wakayama
Query!
Country [157]
0
0
Japan
Query!
State/province [157]
0
0
Yokohama
Query!
Country [158]
0
0
Japan
Query!
State/province [158]
0
0
Yonago
Query!
Country [159]
0
0
Netherlands
Query!
State/province [159]
0
0
Amsterdam
Query!
Country [160]
0
0
Netherlands
Query!
State/province [160]
0
0
Breda
Query!
Country [161]
0
0
Netherlands
Query!
State/province [161]
0
0
Harderwijk
Query!
Country [162]
0
0
Netherlands
Query!
State/province [162]
0
0
Maastricht
Query!
Country [163]
0
0
Netherlands
Query!
State/province [163]
0
0
Tilburg
Query!
Country [164]
0
0
Netherlands
Query!
State/province [164]
0
0
Utrecht
Query!
Country [165]
0
0
Netherlands
Query!
State/province [165]
0
0
Zwolle
Query!
Country [166]
0
0
Norway
Query!
State/province [166]
0
0
Arendal
Query!
Country [167]
0
0
Norway
Query!
State/province [167]
0
0
Bergen
Query!
Country [168]
0
0
Norway
Query!
State/province [168]
0
0
Drammen
Query!
Country [169]
0
0
Norway
Query!
State/province [169]
0
0
Gjøvik
Query!
Country [170]
0
0
Norway
Query!
State/province [170]
0
0
Oslo
Query!
Country [171]
0
0
Poland
Query!
State/province [171]
0
0
Kielce
Query!
Country [172]
0
0
Poland
Query!
State/province [172]
0
0
Poznan
Query!
Country [173]
0
0
Poland
Query!
State/province [173]
0
0
Szczecin
Query!
Country [174]
0
0
Portugal
Query!
State/province [174]
0
0
Coimbra
Query!
Country [175]
0
0
Portugal
Query!
State/province [175]
0
0
Lisbon
Query!
Country [176]
0
0
Portugal
Query!
State/province [176]
0
0
Porto
Query!
Country [177]
0
0
Romania
Query!
State/province [177]
0
0
Bucharest
Query!
Country [178]
0
0
Romania
Query!
State/province [178]
0
0
Cluj-Napoca
Query!
Country [179]
0
0
Romania
Query!
State/province [179]
0
0
Ovidiu
Query!
Country [180]
0
0
Slovakia
Query!
State/province [180]
0
0
Banská Bystrica
Query!
Country [181]
0
0
Slovakia
Query!
State/province [181]
0
0
Bratislava
Query!
Country [182]
0
0
Slovakia
Query!
State/province [182]
0
0
Košice
Query!
Country [183]
0
0
South Korea
Query!
State/province [183]
0
0
Bupyeong-gu
Query!
Country [184]
0
0
South Korea
Query!
State/province [184]
0
0
Busan
Query!
Country [185]
0
0
South Korea
Query!
State/province [185]
0
0
Cheongju-si
Query!
Country [186]
0
0
South Korea
Query!
State/province [186]
0
0
Daegu
Query!
Country [187]
0
0
South Korea
Query!
State/province [187]
0
0
Deagu
Query!
Country [188]
0
0
South Korea
Query!
State/province [188]
0
0
Eunpyeong-gu
Query!
Country [189]
0
0
South Korea
Query!
State/province [189]
0
0
Gangnam-gu
Query!
Country [190]
0
0
South Korea
Query!
State/province [190]
0
0
Goyang-si
Query!
Country [191]
0
0
South Korea
Query!
State/province [191]
0
0
Hwasun-gun
Query!
Country [192]
0
0
South Korea
Query!
State/province [192]
0
0
Nam-gu
Query!
Country [193]
0
0
South Korea
Query!
State/province [193]
0
0
Seongnam
Query!
Country [194]
0
0
South Korea
Query!
State/province [194]
0
0
Seoul
Query!
Country [195]
0
0
South Korea
Query!
State/province [195]
0
0
Suwon
Query!
Country [196]
0
0
South Korea
Query!
State/province [196]
0
0
Yangsan
Query!
Country [197]
0
0
Spain
Query!
State/province [197]
0
0
Badajoz
Query!
Country [198]
0
0
Spain
Query!
State/province [198]
0
0
Barcelona
Query!
Country [199]
0
0
Spain
Query!
State/province [199]
0
0
Hospitalet
Query!
Country [200]
0
0
Spain
Query!
State/province [200]
0
0
Jerez de la Frontera
Query!
Country [201]
0
0
Spain
Query!
State/province [201]
0
0
Las Palmas de Gran Canaria
Query!
Country [202]
0
0
Spain
Query!
State/province [202]
0
0
Madrid
Query!
Country [203]
0
0
Spain
Query!
State/province [203]
0
0
Málaga
Query!
Country [204]
0
0
Spain
Query!
State/province [204]
0
0
Palma
Query!
Country [205]
0
0
Spain
Query!
State/province [205]
0
0
Pamplona
Query!
Country [206]
0
0
Spain
Query!
State/province [206]
0
0
Pozuelo de Alarcón
Query!
Country [207]
0
0
Spain
Query!
State/province [207]
0
0
Santiago de Compostela
Query!
Country [208]
0
0
Spain
Query!
State/province [208]
0
0
Seville
Query!
Country [209]
0
0
Spain
Query!
State/province [209]
0
0
Valencia
Query!
Country [210]
0
0
Spain
Query!
State/province [210]
0
0
Zaragoza
Query!
Country [211]
0
0
Sweden
Query!
State/province [211]
0
0
Gothenburg
Query!
Country [212]
0
0
Switzerland
Query!
State/province [212]
0
0
Baden
Query!
Country [213]
0
0
Switzerland
Query!
State/province [213]
0
0
Fribourg
Query!
Country [214]
0
0
Switzerland
Query!
State/province [214]
0
0
Locarno
Query!
Country [215]
0
0
Taiwan
Query!
State/province [215]
0
0
Changhua County
Query!
Country [216]
0
0
Taiwan
Query!
State/province [216]
0
0
Chiayi City
Query!
Country [217]
0
0
Taiwan
Query!
State/province [217]
0
0
Douliu
Query!
Country [218]
0
0
Taiwan
Query!
State/province [218]
0
0
Hualien City
Query!
Country [219]
0
0
Taiwan
Query!
State/province [219]
0
0
Kaohsiung City
Query!
Country [220]
0
0
Taiwan
Query!
State/province [220]
0
0
Kaohsiung Niao Sung Dist
Query!
Country [221]
0
0
Taiwan
Query!
State/province [221]
0
0
New Taipei City
Query!
Country [222]
0
0
Taiwan
Query!
State/province [222]
0
0
Taichung
Query!
Country [223]
0
0
Taiwan
Query!
State/province [223]
0
0
Tainan
Query!
Country [224]
0
0
Taiwan
Query!
State/province [224]
0
0
Taipei
Query!
Country [225]
0
0
Taiwan
Query!
State/province [225]
0
0
Taoyuan
Query!
Country [226]
0
0
Turkey (Türkiye)
Query!
State/province [226]
0
0
Adana
Query!
Country [227]
0
0
Turkey (Türkiye)
Query!
State/province [227]
0
0
Adapazari
Query!
Country [228]
0
0
Turkey (Türkiye)
Query!
State/province [228]
0
0
Ankara
Query!
Country [229]
0
0
Turkey (Türkiye)
Query!
State/province [229]
0
0
Antalya
Query!
Country [230]
0
0
Turkey (Türkiye)
Query!
State/province [230]
0
0
Edirne
Query!
Country [231]
0
0
Turkey (Türkiye)
Query!
State/province [231]
0
0
Gaziantep
Query!
Country [232]
0
0
Turkey (Türkiye)
Query!
State/province [232]
0
0
Istanbul
Query!
Country [233]
0
0
Turkey (Türkiye)
Query!
State/province [233]
0
0
Izmir
Query!
Country [234]
0
0
Turkey (Türkiye)
Query!
State/province [234]
0
0
Pendik
Query!
Country [235]
0
0
Turkey (Türkiye)
Query!
State/province [235]
0
0
Samsun
Query!
Country [236]
0
0
United Kingdom
Query!
State/province [236]
0
0
Birmingham
Query!
Country [237]
0
0
United Kingdom
Query!
State/province [237]
0
0
East Sussex
Query!
Country [238]
0
0
United Kingdom
Query!
State/province [238]
0
0
Huddersfield
Query!
Country [239]
0
0
United Kingdom
Query!
State/province [239]
0
0
London
Query!
Country [240]
0
0
United Kingdom
Query!
State/province [240]
0
0
Manchester
Query!
Country [241]
0
0
United Kingdom
Query!
State/province [241]
0
0
Torquay
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Secondary sponsor
Nil
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
AstraZeneca
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06890598
Query!
Trial related presentations / publications
Chaft J, Lee JM, Senan S, Neal JW, Nadal E, Negrao MV, Popat S, Garassino MC, Gray JE, Lee SH, Mazieres J, Thomas M, Benes M, Liu H, Liu J, Ma QL, Segall G, Puri T, Wu YL. SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. Future Oncol. 2026 Oct 1:1-10. doi: 10.1080/14796694.2026.2736401. Online ahead of print.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-317-615-4559
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06890598
Download to PDF